A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
This research study is exploring the combination of two new medicines, talquetamab and teclistamab, for individuals living with multiple myeloma. This is for people whose myeloma has either returned after previous treatments or hasn't responded well to them. The study has different stages: first, it aims to find the most suitable dose and schedule for these medicines when given together. Then, it will closely watch for any side effects to make sure the treatment is as safe as possible. Finally, for a specific group of patients whose myeloma has spread outside the bone marrow, the study will check how well this combination therapy works to fight the cancer. Ultimately, the goal is to discover a new and effective treatment option for those with challenging forms of multiple myeloma.
At a glance
What is this study about?
This study is looking into two new medicines, talquetamab and teclistamab, for a type of blood cancer called multiple myeloma. Multiple myeloma affects cells in your bone marrow, and for many people, it can be a challenge to treat, especially when it comes back after treatment or doesn't respond to current medicines. This research is important because it's testing a combination of therapies, which might be more effective than using just one.
The study is happening in different steps. The first part is like figuring out a recipe: the researchers want to find the best amount of each medicine to give and how often to give it. They call this finding the "recommended Phase 2 regimen." Once they think they have a good plan, the next step is to carefully watch for any side effects to make sure the treatment is safe.
In the final part of the study, they will focus on a specific group of people with multiple myeloma where the cancer has spread beyond the bone marrow to other parts of the body. For these individuals, the study will see how well the combination of talquetamab and teclistamab works to shrink the cancer and stop its growth. The hope is that this research will lead to a new and better way to treat multiple myeloma, especially for those who have limited options.
Key takeaways
- This study is testing two new medicines, talquetamab and teclistamab, for challenging multiple myeloma.
- It's for people whose myeloma has come back or isn't responding to current treatments.
- The study aims to find the best dose, check for safety, and see how well the combination fights cancer.
- Participation involves regular visits for treatment and health checks.
- You'll get access to new treatments, but there are potential side effects to consider.
- You can leave the study at any time without affecting your normal care.
Who may be eligible?
To join this study, you would need to have a confirmed diagnosis of multiple myeloma. Importantly, your myeloma must have either returned after previous treatments or not responded well to them. For specific parts of the study, this means you must have had certain standard treatments, like particular types of drugs, and your disease must have worsened despite your last treatment.
You would also need to be generally well enough to take part. This is often checked using a simple score called ECOG, which looks at how well you can carry out daily activities. Depending on the part of the study, you would need an ECOG score of 0, 1, or 2, meaning you are either fully active, able to walk and do light work, or able to care for yourself but unable to do work.
There are also some reasons why you might not be able to join. For example, if you've recently had other trial medicines, specific types of cell transplants, or if your myeloma has spread to your brain or spinal cord. Also, certain other blood conditions like active plasma cell leukemia or Waldenström's macroglobulinemia would prevent you from taking part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do I have a confirmed diagnosis of multiple myeloma?
- Has my multiple myeloma returned or stopped responding to previous treatments?
- Have I had particular standard myeloma treatments before?
- Am I generally well enough for daily activities (ECOG score of 0, 1, or 2)?
- Have I avoided other experimental treatments or certain types of transplants recently?
- Does my myeloma affect my brain or spinal cord, or do I have other specific blood conditions?
What does participation involve?
The study involves receiving two new medicines, talquetamab and teclistamab. You would have regular visits for blood tests, physical examinations, and to receive your treatment. The frequency of visits might change as the study progresses, usually being more frequent at the beginning and then becoming less often. All treatments and study-required assessments would be provided at no cost.
Throughout your participation, doctors and nurses will closely monitor your health and any side effects. You will be asked about your symptoms and how you are feeling at each visit. The total length of your participation would depend on how your myeloma responds to the treatment and what the study doctors decide is best for you. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.
Potential risks and benefits
Locations (40)
- University of Alabama at Birmingham, Comprehensive Cancer CenterVerified postcodeBirmingham, United States
- University of Arkansas for Medical SciencesVerified postcodeLittle Rock, United States
- Colorado Blood Cancer InstituteVerified postcodeDenver, United States
- Emory UniversityVerified postcodeAtlanta, United States
- Mayo ClinicVerified postcodeRochester, United States
- Washington University St. Louis School Medicine Siteman Cancer CenterVerified postcodeSt Louis, United States
- Mount Sinai Medical CenterVerified postcodeNew York, United States
- Memorial Sloan Kettering Cancer CenterVerified postcodeNew York, United States
- Atrium HealthVerified postcodeCharlotte, United States
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer CenterVerified postcodeWinston-Salem, United States
- Cleveland ClinicVerified postcodeCleveland, United States
- Oregon Health And Science UniversityVerified postcodePortland, United States
Common questions
What is multiple myeloma?
Multiple myeloma is a type of cancer that develops from plasma cells, a type of white blood cell, found in the bone marrow. It can affect your bones, kidneys, immune system, and red blood cell count.
What do 'relapsed' or 'refractory' mean in this study?
'Relapsed' means your multiple myeloma has returned after getting better with previous treatment. 'Refractory' means your multiple myeloma didn't respond or stopped responding to the treatment you were receiving.
Are talquetamab and teclistamab approved medicines?
These are investigational medicines, meaning they are still being studied and are not yet fully approved for general use. They are given as part of a clinical trial to see if they are safe and effective.
Will I know if I'm getting the active treatment or a placebo?
In this specific study, all participants will receive the active study medicines, talquetamab and teclistamab. There is no placebo group.
Who can I talk to if I have more questions?
You should discuss any questions or concerns you have about this study with your doctor or the research team. They can provide more detailed information tailored to your specific situation.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.